FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)

View source ↗

Summary

The FDA approved a supplemental application for CONTRAVE EXTENDED-RELEASE, a fixed-dose combination of naltrexone hydrochloride and bupropion hydrochloride, dev…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• CONTRAVE EXTENDED-RELEASE (Naltrexone hydrochloride and bupropion hydrochloride)

Snippet

SUPPL AP for CONTRAVE EXTENDED-RELEASE (NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE)